Glycemic and lipid responses to glucomannan in Thais with type 2 diabetes mellitus.
Artículo
en Inglés
| IMSEAR
| ID: sea-38719
ABSTRACT
OBJECTIVE:
To evaluate the benefits of glucomannan supplement on glycemic and lipid controls in type 2 diabetic patients. MATERIAL ANDMETHOD:
A single-blind, placebo-controlled, crossover trial with two treatments separated by a 2-week washout period was performed in 10 men and 10 women with type 2 diabetes mellitus. Two separated protocols of experiments were sequentially followed. Initially, purified glucomannan (1 g) or placebo was ingested 30 min before 75-g glucose load to evaluate their effects on glucose absorption and insulin secretion in oral glucose tolerance test (OGTT). Later, the glycemic and lipid changes after 4-week intervention with 3 g/day glucomannan comparing to the placebo were determined. The standard OGTT was performed before and after ending of each intervention.RESULTS:
Glucomannan taken before performing the OGTT can lower the rise of blood glucose and insulin from 1 to 2 hour in comparison with the placebo, though a statistically significance of insulin was not achieved. Long-term glucomannan supplement significantly reduced the 120-min glucose area under the curve of OGTT. Glucomannan also decreased the rise of low-density lipoprotein cholesterol (LDL-C). Reductions of HOMA-insulin resistance index and body mass index were detected in glucomannan-treated group though the former was shown only in females. No within- and between-group differences of insulin, fructosamine, and other lipids were observed in glucomannan- nor placebo- treated groups.CONCLUSION:
In type 2 diabetes, pre-prandial glucomannan ingestion attenuated a rise of blood glucose without significantly affecting insulin levels. Long-term supplement of glucomannan to the regular diabetic regimen lessened post challenge glucose AUC and impeded the rise of LDL-C. Supplement of glucomannan may be beneficial to the glycemic and lipid controls in type 2 diabetes mellitus.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Tailandia
/
Glucemia
/
Anciano
/
Femenino
/
Humanos
/
Masculino
/
Resistencia a la Insulina
/
Catárticos
/
Índice de Masa Corporal
/
Indicadores de Salud
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio de etiología
/
Guía de Práctica Clínica
/
Estudio pronóstico
/
Factores de riesgo
País/Región como asunto:
Asia
Idioma:
Inglés
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS